Predictors of outcome in dogs with subcutaneous or intramuscular hemangiosarcoma
Authors:
- Kai-Biu ShiuKSKai-Biu Shiu
- Andrea B. FloryAFAndrea B. Flory
- Christie L. AndersonCAChristie L. Anderson
- Jackie WypijJWJackie Wypij
- Corey SabaCSCorey Saba
- Heather WilsonHWHeather Wilson
- Ilene KurzmanIKIlene Kurzman
- Ruthanne ChunRCRuthanne Chun
- 15 February 2011
- journal article
- research article
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 238 (4) , 472-479
Abstract
Objective—To identify prognostic factors in a large group of dogs with subcutaneous or intramuscular hemangiosarcoma (HSA) or both. Design—Multi-institutional retrospective cohort study. Animals—71 dogs with subcutaneous or intramuscular HSA. Procedures—Medical records of affected dogs were reviewed. The following factors were evaluated for an association with outcome: dog age and sex, clinical signs, anemia, thrombocytopenia, neutrophilia, tumor stage at diagnosis, achievement of complete excision, intramuscular involvement, presence of gross disease, tumor recurrence, and treatment. Results—Of the 71 cases identified, 16 (29%) had intramuscular tumor involvement. For all dogs, median time to tumor progression and overall survival time (OST) were 116 and 172 days, respectively; 25% survived to 1 year. Univariate analysis identified presence of clinical signs or metastasis at diagnosis, dog age, tumor size, use of any surgery, and presence of gross disease as predictors of time to tumor progression and OST. There was no significant difference in survival time between dogs with respect to type of HSA. Multivariate analysis confirmed that adequate local tumor control, tumor diameter ≤ 4 cm, presence of metastasis at diagnosis, and presence of gross disease were significantly associated with OST. Conclusions and Clinical Relevance—Subcutaneous and intramuscular HSA remains a heterogeneous group of tumors that generally carries a poor prognosis. Adequate local control of smaller tumors with no associated clinical signs or metastasis may provide the best chance of long-term survival.Keywords
This publication has 25 references indexed in Scilit:
- Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001–2006)Journal of the American Veterinary Medical Association, 2008
- Clinical Stage, Therapy, and Prognosis in Canine Anal Sac Gland CarcinomaJournal of Veterinary Internal Medicine, 2007
- Femoral compartment syndrome due to haemangiosarcoma in the semimembranosus muscle in a dogJournal of Small Animal Practice, 2006
- Canine Mast Cell Tumors: Correlation of Apoptosis and Proliferation Markers with PrognosisJournal of Veterinary Internal Medicine, 2006
- Surgery and Doxorubicin in Dogs With HemangiosarcomaJournal of Veterinary Internal Medicine, 1996
- Cutaneous Hemangiosarcoma in 25 Dogs: A Retrospective StudyJournal of Veterinary Internal Medicine, 1994
- Canine oral malignant melanoma: Prognostic utility of an alternative staging systemJournal of Small Animal Practice, 1994
- Chemotherapy of Canine Hemangiosarcoma With Doxorubicin and CyclophosphamideJournal of Veterinary Internal Medicine, 1993
- Canine Oral Melanoma: Comparison of Surgery Versus Surgery Plus Corynebacterium parvumCancer Investigation, 1986
- Microangiopathic Hemolytic Anemia Associated with Radiation-Induced HemangiosarcomasVeterinary Pathology, 1980